DAWN
Day One Biopharmaceuticals Inc.
$6.79
-$0.02(-0.29%)
10
Overall
--
Value
10
Tech
--
Quality
Market Cap
$690.28M
Volume
1.00M
52W Range
$5.64 - $16.76
Target Price
$24.56
Order:
Income Statement
| Metric | Trend | Chart | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | -- | -- | -- | $131.2M | ||
| Total Revenue | -- | -- | -- | $131.2M | ||
| GROSS PROFIT | ||||||
| Gross Profit | -- | -- | -- | $131.2M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $72.7M | $146.9M | $206.1M | $348.4M | ||
| Research & Development | $43.6M | $85.6M | $130.5M | $227.7M | ||
| Research Expense | $43.6M | $85.6M | $130.5M | $227.7M | ||
| Selling, General & Administrative | $29.2M | $61.3M | $75.5M | $115.5M | ||
| General & Administrative Expenses | $29.2M | $61.3M | $75.5M | $115.5M | ||
| Depreciation & Amortization | $20.0K | $63.0K | -- | -- | ||
| Depreciation & Amortization | $20.0K | -- | -- | -- | ||
| Amortization | $179.0K | $468.0K | $347.0K | $2.8M | ||
| Other Operating Expenses | $-953.0K | -- | -- | -- | ||
| OPERATING INCOME | ||||||
| Operating income | $-72.7M | $-146.9M | $-206.1M | $-217.3M | ||
| EBITDA | $-72.6M | $-141.7M | $-188.5M | $-86.3M | ||
| NON-OPERATING ITEMS | ||||||
| Interest Expense (Non-Operating) | $-4.0K | $-4.7M | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $4.0K | $-4.7M | -- | -- | ||
| Gain on Sale of Securities | -- | $4.7M | $17.2M | $127.7M | ||
| Other Income/Expense | $15.0K | $4.7M | $-17.1M | $-128.9M | ||
| Other Special Charges | $-15.0K | $-18.0K | $-40.0K | $1.2M | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-72.8M | $-142.2M | $-188.9M | $-88.4M | ||
| Pre-Tax Income | $-72.8M | $-142.2M | $-188.9M | $-83.1M | ||
| INCOME TAX | ||||||
| Tax Provision | -- | -- | -- | $7.1M | ||
| NET INCOME | ||||||
| Net Income | $-72.8M | $-142.2M | $-188.9M | $-95.5M | ||
| Net Income (Continuing Operations) | $-72.8M | $-142.2M | $-188.9M | $-95.5M | ||
| Net Income (Discontinued Operations) | $-72.8M | $-142.2M | $-188.9M | $-95.5M | ||
| Net Income (Common Stockholders) | $-172.7M | $-142.2M | $-188.9M | $-95.5M | ||
| TOTALS | ||||||
| Total Expenses | $72.7M | $146.9M | $206.1M | $348.4M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $37.0M | $65.5M | $79.8M | $93.2M | ||
| Average Shares Outstanding (Diluted) | -- | $65.5M | $79.8M | $93.2M | ||
| Shares Outstanding | $62.0M | $73.6M | $87.4M | $101.4M | ||
| Basic EPS | $-4.62 | $-2.17 | $-2.37 | $-1.02 | ||
| Basic EPS (Continuing Operations) | $-4.62 | $-2.17 | $-2.37 | $-1.02 | ||
| Diluted EPS | $-4.62 | $-2.17 | $-2.37 | $-1.02 | ||
| Diluted EPS (Continuing Operations) | -- | $-2.17 | $-2.37 | $-1.02 | ||
| OTHER METRICS | ||||||
| Accrued Preferred Stock Dividends | $100.0M | -- | -- | -- | ||
| Minority Interests | $2.1M | -- | -- | -- | ||
| Other Gand A | $29.2M | $61.3M | $75.5M | $115.5M | ||
| Otherunder Preferred Stock Dividend | $100.0M | -- | -- | -- | ||
| Preferred Stock Dividends | $100.0M | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DAWN | $6.79 | -0.3% | 1.00M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Day One Biopharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW